Can Doravirine Tablets Be Crushed?
No specific data exists on crushing doravirine tablets, and the FDA label does not address this administration method, so crushing doravirine should be avoided unless absolutely necessary. If patients cannot swallow tablets, consider switching to alternative antiretroviral regimens that have established safety data for crushing or are available in liquid formulations.
Key Evidence and Reasoning
The FDA drug label for doravirine (DELSTRIGO and PIFELTRO) provides no guidance on crushing tablets 1. This absence of data is clinically significant because:
- Crushing can alter drug exposure - potentially leading to treatment failure, resistance development, or toxicity 2, 3
- Doravirine's pharmacokinetic profile is well-characterized only for intact tablets - any alteration in formulation could unpredictably affect absorption 1
- The film-coated tablet contains specific inactive ingredients (hypromellose acetate succinate, carnauba wax coating) that may serve functional purposes in drug delivery 1
Clinical Context: When Crushing Becomes Necessary
The 2020 IAS-USA guidelines specifically address situations requiring crushed or liquid antiretroviral formulations, particularly in patients with chemotherapy-induced severe mucositis 4. However, these guidelines explicitly state that crushing bictegravir/tenofovir alafenamide/emtricitabine is not recommended 4, establishing precedent that not all modern antiretrovirals are suitable for crushing.
Notably, doravirine-containing regimens are not recommended to initiate during pregnancy due to inadequate data 5, suggesting a conservative approach to this medication when data are limited.
Evidence from Other Antiretrovirals
Research on crushing other HIV medications provides important context:
- Dolutegravir (Triumeq®): Crushing increases dolutegravir exposure by 26% (AUC) and 30% (Cmax), though investigators concluded this could be acceptable given it doesn't exceed exposure with food 6
- Darunavir/cobicistat/emtricitabine/TAF: Crushing decreased tenofovir alafenamide bioavailability by 19-29%, though considered potentially acceptable given the wide therapeutic window 7
These studies demonstrate that crushing consistently alters pharmacokinetics, even when deemed clinically manageable.
Practical Recommendations
If a patient cannot swallow doravirine tablets:
First-line approach: Switch to an alternative regimen with established crushing data or liquid formulations
- Raltegravir, dolutegravir, or bictegravir-based regimens are recommended to minimize drug-drug interactions in complex situations 4
- Consider regimens where crushing data exists (though note bictegravir combinations are not recommended for crushing)
If doravirine must be continued:
- Consult with an HIV specialist and clinical pharmacist
- Consider checking drug-specific levels if crushing is attempted (similar to recommendations for DOACs in enteral feeding) 8
- Monitor viral load more frequently to detect potential treatment failure
Avoid crushing if:
- Alternative effective regimens are available
- The patient's clinical situation allows time for regimen optimization
Important Caveats
- Healthcare worker safety: Crushing exposes personnel to drug particles that may be carcinogenic, teratogenic, or allergenic 2
- Stability concerns: Doravirine's degradation products have been characterized, and repackaging can affect drug stability 9
- No reversal of crushing decision: Once a tablet is crushed, there's no way to restore its original pharmacokinetic profile
The absence of crushing data for doravirine, combined with established risks of crushing antiretrovirals and availability of alternative regimens, makes switching to a more appropriate formulation the preferred strategy over crushing doravirine tablets.